{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,27]],"date-time":"2025-07-27T07:23:38Z","timestamp":1753601018497,"version":"3.40.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.gastrohep.2012.07.001","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T14:33:11Z","timestamp":1354717991000},"page":"81-85","source":"Crossref","is-referenced-by-count":5,"title":["Esclerosis m\u00faltiple como efecto adverso de los agentes antifactor de necrosis tumoral alfa: una complicaci\u00f3n infrecuente pero relevante de infliximab en la enfermedad de Crohn"],"prefix":"10.1016","volume":"36","author":[{"given":"Alberto","family":"Mir Sub\u00edas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Garc\u00eda-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berta","family":"Sebasti\u00e1n Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Ollero Domenche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Garc\u00eda G\u00e1mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gomoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2012.07.001_bib0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.crohns.2010.02.002","article-title":"On the updated ECCO consensus guidelines for medical management of Crohn's disease","volume":"5","author":"Esser","year":"2011","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0010","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2006.02786.x","article-title":"Review article: Infliximab therapy for inflammatory bowel disease--seven years on","volume":"23","author":"Rutgeerts","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0015","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.2165\/00003495-200767170-00005","article-title":"Crohn's disease: a review of current treatment with a focus on biologics","volume":"67","author":"Pan\u00e9s","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0020","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.2049","article-title":"The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy","volume":"20","author":"Winthrop","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0030","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease Crohn's Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn's disease: TREAT Registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1002\/ibd.23011","article-title":"Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics","author":"Singh","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0055","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM198909143211115","article-title":"Concurrence of multiple sclerosis and inflammatory bowel disease","volume":"321","author":"Sadovnick","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0060","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"Suppl","key":"10.1016\/j.gastrohep.2012.07.001_bib0065","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1002\/ana.410360732","article-title":"MS COSTAR: a computerized patient record adapted for clinical research purposes","volume":"36","author":"Paty","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0070","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMcp053247","article-title":"Optic Neuritis","volume":"354","author":"Balcer","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0075","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0080","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0025-7753(05)72181-3","article-title":"Multiple sclerosis after treatment with anti-TNF-alpha antibodies","volume":"125","author":"Munteis-Olivas","year":"2005","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0085","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0095","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(91)91909-E","article-title":"Overview of azathioprine treatment in multiple sclerosis","volume":"338","author":"Yudkin","year":"1991","journal-title":"The Lancet"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/WNF.0b013e31824644e6","article-title":"Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort","volume":"35","author":"Kallweit","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study","author":"Fernandez","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0110","doi-asserted-by":"crossref","first-page":"265","DOI":"10.33588\/rn.4905.2009447","article-title":"Natalizumab in multiple sclerosis","volume":"49","author":"Rio-Izquierdo","year":"2009","journal-title":"Rev Neurol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0115","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.22606","article-title":"Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1","volume":"70","author":"Bozic","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0120","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.gastro.2007.03.024","article-title":"Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial","volume":"132","author":"Targan","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2012.07.001_bib0125","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn's disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570512002233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570512002233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:58:14Z","timestamp":1745395094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570512002233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0210570512002233"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2012.07.001","relation":{},"ISSN":["0210-5705"],"issn-type":[{"type":"print","value":"0210-5705"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}